Research Grade Tebotelimab

Catalog No.

DHD30407

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

[V-kappa’-VH-h-CH2-CH3_V-kappa-VH’]2

Clonality

Monoclonal

Target

FDC, LAG3, Lymphocyte activation gene 3 protein, CD223, sLAG-3, LAG-3, Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P18627 & Q15116

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Bispecific, MGD-013, CAS: 2245725-04-4

Clone ID

Tebotelimab

Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study., PMID:40445839

The emerging role of lymphocyte-activation gene 3 targeting in the treatment of solid malignancies., PMID:40344213

Tebotelimab Is Safe and Effective Across Multiple Cancer Types., PMID:37921450

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial., PMID:37857711

MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma., PMID:33263418

Document Download

Research Grade Tebotelimab.pdf